Daito Pharmaceutical
4577.TPharmaceutical
Filed as Daito Pharmaceutical Co.,Ltd. (2022-08–2026-08)
Financials · Consolidated
| Fiscal year ended | 2026-05 | 2025-05 | 2024-05 | 2023-05 | 2022-05 | 2021-05 |
|---|---|---|---|---|---|---|
| Revenue | ¥50.6bn | ¥50.6bn | ¥46.9bn | ¥45.1bn | ¥43.5bn | ¥48.7bn |
| Operating income | ¥3.6bn | ¥2.6bn | ¥3.9bn | ¥5.2bn | ¥6.6bn | ¥5.9bn |
| Ordinary income | ¥3.8bn | ¥2.7bn | ¥3.9bn | ¥5.2bn | ¥6.7bn | ¥6.1bn |
| Net income (owners) | ¥3.2bn | ¥1.9bn | ¥3.3bn | ¥3.6bn | ¥4.7bn | ¥4.2bn |
| Total assets | ¥73.3bn | ¥78.0bn | ¥77.7bn | ¥70.6bn | ¥64.9bn | ¥57.7bn |
| Net assets / equity | ¥52.9bn | ¥52.1bn | ¥52.3bn | ¥51.0bn | ¥47.7bn | ¥41.9bn |
| Operating cash flow | ¥9.4bn | ¥5.9bn | ¥5.2bn | ¥4.2bn | ¥4.4bn | ¥5.2bn |
| EPS (basic) | ¥107.49 | ¥62.74 | ¥105r | ¥113.81r | ¥152.46r | ¥141.37r |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-06-01 → 2026-05-31 | Annual | 198 figures · EDINET |
| 2025-06-01 → 2025-11-30 | Half-year | 67 figures · EDINET |
| 2024-06-01 → 2025-05-31 | Annual | 198 figures · EDINET |
| 2024-06-01 → 2024-11-30 | Half-year | 67 figures · EDINET |
| 2023-06-01 → 2024-05-31 | Annual | 200 figures · EDINET |
| 2023-06-01 → 2024-02-29 | Quarterly Q3 | 47 figures · EDINET |
| 2023-06-01 → 2023-11-30 | Quarterly Q2 | 71 figures · EDINET |
| 2023-06-01 → 2023-08-31 | Quarterly Q1 | 44 figures · EDINET |
| 2022-06-01 → 2023-05-31 | Annual | 200 figures · EDINET |
| 2022-06-01 → 2023-02-28 | Quarterly Q3 | 46 figures · EDINET |
| 2022-06-01 → 2022-11-30 | Quarterly Q2 | 70 figures · EDINET |
| 2022-06-01 → 2022-08-31 | Quarterly Q1 | 43 figures · EDINET |
| 2021-06-01 → 2022-05-31 | Annual | 198 figures · EDINET |
22 more reports are still being processed.